Gibney Anthony S 4

What Happened

• Anthony S. Gibney, Aura Biosciences' Chief Financial and Business Officer, was granted a total of 200,000 shares on 2026-03-02 through two awards: 71,245 RSUs and 128,755 derivative shares (award/option-like). Both awards show an acquisition price of $0 (they are compensation grants, not open-market purchases).

Key Details

• Transaction date: 2026-03-02; Form 4 filed 2026-03-03 (timely filing).
• Awards: 71,245 RSUs (acquisition code A) and 128,755 derivative award (code A, derivative).
• Price/Value: $0 per share (grant of equity compensation).
• Vesting (from filing footnotes):
  • 71,245 RSUs: vest in four substantially equal annual installments beginning January 15, 2027, subject to continued service. (F1)
  • 128,755 derivative award: 25% vest on February 1, 2027; remaining 75% vests pro rata over the following 36 months, subject to continued service. (F2)
• Shares owned after transaction: not specified in the filing.

Context

• These are compensation awards (RSUs/derivative awards) that vest over time and require continued service; they are not open-market buys or immediate sales and therefore reflect planned compensation rather than an immediate trading signal.
• The awards were reported promptly (filed the next day), and no sales, exercises for cash, or tax-withholding transactions were reported in this filing.